Abstract: In June 2018, US Food and Drug Administration(FDA) and European Commission had totally approved 19 new drugs, including new molecular entities, new active ingredient, new biologics and new line extensions(new indications and new formulations). In this article, new molecular entities, new active ingredients and new biologics receiving their first global approval were analyzed with emphasis on the outcomes of clinical trials and development histories.